Frank S. Czerwiec, MD, PhD

Chief Medical Officer
Sparrow Pharmaceuticals, Inc.
Miami, United States

Disclosure information not submitted.

Presentation(s):

• SAT-625 - Analysis of Cardiometabolic Effects from A Randomized, Placebo-Controlled, Clinical Trial of Clofutriben in Adults with Diabetes

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SAT-634 - Prevalence of Elevated Cortisol in Difficult-to-Control Type 2 Diabetes: Interim Results for CAPTAIN-T2D, a Phase 2 Trial of Clofutriben

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT